Optivar (azelastine 0.05% ophthalmic)

Optivar (azelastine 0.05% ophthalmic) is filed as Ophthalmic Antihistamine. The sections below restate public label fields stored for this profile.

Class
Ophthalmic Antihistamine
Generic name
azelastine 0.05% ophthalmic
Route
NASAL
Dosage forms
3 DOSAGE FORMS AND STRENGTHS Azelastine hydrochloride nasal spray is a nasal spray solution. Each spray of azelastine hydrochloride nasal spray delivers a volume of 0.137 mL solution containing 137 mcg of azelastine hydrochloride. Azelastine hydrochloride nasal spray: 137 mcg of azelastine hydrochloride in each 0.137 mL spray. ( 3 )
Generic available
Yes
Manufacturer
A-S Medication Solutions

Approved uses

Azelastine hydrochloride ophthalmic solution 0.05% is indicated for the treatment of itching of the eye associated with allergic conjunctivitis.

How it works

Azelastine Hydrochloride is a relatively selective histamine H 1 antagonist and an inhibitor of the release of histamine and other mediators from cells (e.g. mast cells) involved in the allergic response. Based on in-vitro studies using human cell lines, inhibition of other mediators involved in allergic reactions (e.g. leukotrienes and PAF) has been demonstrated with azelastine hydrochloride. Decreased chemotaxis and activation of eosinophils has also been demonstrated. Pharmacokinetics and Metabolism: Absorption of azelastine following ocular administration was relatively low. A study in symptomatic patients receiving one drop of azelastine hydrochloride ophthalmic solution 0.05% in each eye two to four times a day (0.06 to 0.12 mg azelastine hydrochloride) demonstrated plasma concentrations of azelastine hydrochloride to generally be between 0.02 and 0.25 ng/mL after 56 days of treatment. Three of nineteen patients had quantifiable amounts of N-desmethylazelastine that ranged from 0.25–0.87 ng/mL at Day 56. Based on intravenous and oral administration, the elimination half-life, steady-state volume of distribution and plasma clearance were 22 hours, 14.5 L/kg and 0.5 L/h/kg, respectively. Approximately 75% of an oral dose of radiolabeled azelastine hydrochloride was excreted in the feces with less than 10% as unchanged azelastine. Azelastine hydrochloride is oxidatively metabolized to the principal metabolite, N-desmethylazelastine, by the cytochrome P450 enzyme system. In-vitro studies in human plasma indicate that the plasma protein binding of azelastine and N-desmethylazelastine are approximately 88% and 97%, respectively. Clinical Trials: In a conjunctival antigen challenge study, azelastine hydrochloride ophthalmic solution 0.05% was more effective than its vehicle in preventing itching associated with allergic conjunctivitis. Azelastine hydrochloride ophthalmic solution 0.05% had a rapid (within 3 minutes) onset of effect and a duration of effect of approximately 8 hours for the prevention of itching. In environmental studies, adult and pediatric patients with seasonal allergic conjunctivitis were treated with azelastine hydrochloride ophthalmic solution 0.05% for two to eight weeks. In these studies, azelastine hydrochloride ophthalmic solution 0.05% was more effective than its vehicle in relieving itching associated with allergic conjunctivitis.

Warnings and precautions

Azelastine hydrochloride ophthalmic solution 0.05% is for ocular use only and not for injection or oral use.

Contraindications

Azelastine hydrochloride ophthalmic solution 0.05% is contraindicated in persons with known or suspected hypersensitivity to any of its components.

Common side effects

Bitter taste (Common); Headache (Common); Somnolence (Common); Dysesthesia (Common); Rhinitis (Common); Nasal burning (Common); Pharyngitis (Common); Epistaxis (Common)

Dosage and administration

The recommended dose is one drop instilled into each affected eye twice a day.

Drug interactions

7 DRUG INTERACTIONS 7.1 Central Nervous System Depressants Concurrent use of azelastine hydrochloride nasal spray with alcohol or other central nervous system depressants should be avoided because reductions in alertness and impairment of central nervous system performance may occur [see Warnings and Precautions ( 5.1 )].

Common questions

What is Optivar approved to treat?

According to its FDA label, Optivar (azelastine 0.05% ophthalmic) is approved for: Azelastine hydrochloride ophthalmic solution 0.05% is indicated for the treatment of itching of the eye associated with allergic conjunctivitis. For medical advice, please talk to your prescriber or pharmacist.

What class of drug is Optivar?

Optivar (azelastine 0.05% ophthalmic) belongs to the Ophthalmic Antihistamine class of medications.

What form does Optivar come in?

The FDA label lists Optivar (azelastine 0.05% ophthalmic) as: 3 DOSAGE FORMS AND STRENGTHS Azelastine hydrochloride nasal spray is a nasal spray solution. Each spray of azelastine hydrochloride nasal spray delivers a volume of 0.137 mL solution containing 137 mcg of azelastine hydrochloride. Azelastine hydrochloride nasal spray: 137 mcg of azelastine hydrochloride in each 0.137 mL spray. ( 3 ); nasal route. Available strengths and packaging vary by manufacturer.

Is there a generic version of Optivar?

Yes. A generic version of Optivar (azelastine 0.05% ophthalmic) is available in the U.S. Ask your pharmacist about substitution.

Does Optivar have a Boxed Warning?

Our ingest of the FDA label for Optivar (azelastine 0.05% ophthalmic) does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.

How much does Optivar cost?

Public CMS NADAC pricing for Optivar (azelastine 0.05% ophthalmic) is in the range Retail prices vary widely by pharmacy, insurance, and location. Check with your pharmacy or use tools like GoodRx for current pricing.. Retail price varies by pharmacy, insurance, and manufacturer coupons.

Is Optivar currently under recall?

The FDA Enforcement Report does not show an active/ongoing recall for Optivar (azelastine 0.05% ophthalmic) in our latest ingest. Recall data can change daily — verify at FDA.gov.

When was Optivar approved by the FDA?

The FDA record lists the approval date for Optivar (azelastine 0.05% ophthalmic) as 2009-04-30.

Who makes Optivar?

The FDA label lists A-S Medication Solutions as a labeler/manufacturer of Optivar (azelastine 0.05% ophthalmic). Multiple firms may market generics of the same molecule.

How should Optivar be stored?

The FDA label states: "Azelastine hydrochloride ophthalmic solution, USP 0.05% is supplied as follows: Azelastine hydrochloride ophthalmic solution, USP 0.05% 6 mL (NDC#62332-506-06) solution in a 10 mL LDPE container with LDPE nozzle and a wh…" Follow the packaging insert for the authoritative guidance.

On this site

Related medications in this class or category

Loading full data from Know Your Drugs Institute…